# US 12,760,070 B2 · Cyclic cell penetrating peptides and methods of making and using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,760,070 B2
- Document ID: US12760070B2
- Status: Granted
- Kind: B2
- Application number: 19/329,358
- Filed: 2025-09-15
- Published: 2026-01-08
- Granted: 2026-10-13
- Earliest claimed: 2016-11-22
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Dehua Pei; Ziqing Qian
- Web page: https://patentgrep.com/patent/US12760070B2

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61P 35/00: Antineoplastic agents
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.

## Claims

### Claim 1

A compound comprising;
i. a cyclic cell penetrating 8 amino acid peptide, wherein the amino acids are connected through peptide bonds, that contains;
a. one arginine within two amino acids of another arginine;
b. a phenylalanine within two amino acids of another phenylalanine; and
ii. an exocyclic cargo moiety conjugated to a side chain of the cell penetrating peptide wherein the conjugation is through glutamine and wherein the cargo comprises an amino acid sequence that targets an enzyme.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the cargo moiety also comprises a therapeutic moiety and a linker moiety.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the cargo moiety also comprises a therapeutic moiety and a linker moiety.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the cargo moiety also comprises one or more detectable moieties or one or more therapeutic moieties or any combination thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the cyclic cell penetrating peptide comprises at least three amino acids with a hydrophobic side chain.

### Claim 6 (depends on 5)

The compound of claim 5, wherein at least one of the amino acids with a hydrophobic side chain is a glycine.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the cyclic cell penetrating peptide comprises at least three amino acids which have a hydrophobic side chain, wherein at least two amino acids having a hydrophobic side chain are consecutive.

### Claim 8 (depends on 7)

The compound of claim 7, wherein at least one of the amino acids with a hydrophobic side chain is a glycine.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the cyclic cell penetrating peptide comprises at least two consecutive L amino acids.

### Claim 10 (depends on 1)

The compound of claim 1, wherein each amino acid of the cyclic cell penetrating peptide is a natural amino acid.